 Some authors have argued that a regulated market in oocytes could minimize ethical concerns raised by the commercialization of oocytes and could be consistent with respect for women (Resnik 2001; Gruen 2007). Researchers are also investigating the use of alternative sources of oocytes, including animal oocytes, fetal oocytes, oocytes from adult ovaries obtained post mortem or during operation, and stem cell-derived oocytes. Scientists have already succeeded in creating human oocytes from embryonic stem cells (Ma et al. 2017; Saitou &amp; Miyauchi 2016). Finally, another option is ‘egg-sharing’ where couples who are undergoing IVF for reproductive purposes have the option to donate one or two of their oocytes in return for a reduced fee for their fertility treatment. The advantage of this system is that it avoids exposing women to extra risks – these women were undergoing IVF in any case (Roberts &amp; Throsby 2008).